High risk, high reward: An analysis of outcomes for candidates awaiting hepatic re-transplantation
Journal Title: Annals of Hepatology - Year 2016, Vol 15, Issue 6
Abstract
Background. Liver re-transplantation (re-OLT) remains the only feasible option for patients with graft failure following liver transplantation. Sparse resources and a growing waitlist mandate that available grafts are allocated properly. We studied the differences in patient demographics, characteristics, and survival for those listed for re-OLT in a region with prolonged wait times. Material and methods. We performed a single-center retrospective study, from 2005 to 2013, of adult candidates listed for liver re-OLT at a tertiary care center within United Network for Organ Sharing (UNOS) region 1. Results. Of the 48 patients listed for re-OLT, 1(2%) improved while waiting, 14(29%) died while waiting, and 33(69%) underwent re-OLT. Those re-transplanted represented 11% of the center’s adult liver transplant volume during the same time period. Comparing those who died while waiting to those who achieved re-OLT, there was no significant difference in age (median 52 vs. 48 years, p=0.56) or MELD at second listing (median 29 vs. 26, p = 0.90). Waitlisted candidates who failed to achieve re-transplant died on average of 15.5 days (IQR 36 days) days after re-listing. Those re-transplanted achieved 3-year survival of 70% and there was no significant difference in 3-year survival of those re-transplanted within or beyond 90 days of first transplant (70% vs. 69.5%, p = 0.28). Conclusions. In conclusion, re-OLT is the only viable option for candidates with nonreversible liver graft failure. Inability to achieve re-OLT leads to nearly assured and expeditious death. Despite technical challenges, in experienced hands excellent long term survival following re-OLT can be achieved.
Authors and Affiliations
Jigesh Shah, Madhukar Patel, Johannes Kratz, James Markmann, Parsia Vagefi
Keywords
Related Articles
- EP ID EP207227
- DOI -
- Views 99
- Downloads 0
Renal and circulatory effects of large volume plasma expansion in patients with hepatorenal syndrome type 1
Introduction. Hepatorenal syndrome type I (HRS I) may be a consequence of circulatory dysfunction in cirrhotic patients with portal hypertension. This uncontrolled interventional pilot study examines the hemodynamic and...
Noninvasive assessment of hepatic fibrosis using gadoxetate-disodium-enhanced 3T MRI
Introduction. Gadoxetate-disodium is a liver-specific MR contrast agent absorbed by hepatocytes via organic anion transporting polypeptide 1B3 and is excreted into the biliary system by multidrug resistance-associated pr...
Hepatic venous pressure gradient measurement in pre-primary and primary prophylaxis of variceal hemorrhage
Pharmacological therapy of portal hypertensión can be accomplished according to different objectives. Among them, pre-primary prophylaxis aims to avoid / delay esophageal varices development while the target of primary p...
Preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: a single center analysis
Background and aim. The effect of preoperative transcatheter arterial chemoembolization (TACE) on the short- and long-term outcome of resectable hepatocellular carcinoma (HCC) is controversial. We conducted a retrospecti...
Differences in hepatic expression of iron, inflammation and stress-related genes in patients with nonalcoholic steatohepatitis
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. We have previously shown that hepatic reticuloendothelial system (RES) iron deposition is associated with an advanced...